CVRx Initiates Large-Scale Clinical Trial to Broaden Heart Failure Treatment Indications
CVRx Inc. has launched the BENEFIT-HF clinical trial to assess its Barostim neuromodulation device in a larger heart failure population, potentially tripling the eligible patient base. The extensive trial will enroll 2,500 patients across numerous centers in the US and Germany, marking one of the largest cardiac device studies in heart failure to d…